Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 23
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Intellia Therapeutics Inc
NTLA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$11.16
-0.49
-4.21%
Dern. MÀJ: Oct 22, 7:28 PM
$11.14
-0.51
-4.38%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Intellia Therapeutics Financials
Intellia Therapeutics (NTLA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.79) by 1.27 percent. This is a 18.37 percent increase over losses of $(0.98) per
Benzinga Newsdesk
PRO
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimates
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share
Benzinga Newsdesk
PRO
Intellia Therapeutics Q1 EPS $(0.81) Beats $(0.90) Estimate, Sales $15.048M Beat $14.793M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.90) by 10 percent. This is a 26.36 percent increase over losses of $(1.10) per share
Benzinga Newsdesk
PRO
Intellia Therapeutics Q4 EPS $(0.83) Beats $(0.96) Estimate, Sales $23.017M Beat $12.812M Estimate
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.96) by 13.72 percent. This is a 34.65 percent increase over losses of $(1.27) per share
Benzinga Newsdesk
Earnings Scheduled For February 26, 2026
Benzinga Insights
Earnings Preview For Intellia Therapeutics
Benzinga Insights
